|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,173,107: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,173,107?
US Patent 8,173,107 was issued on May 8, 2012, assigned to Merck Sharp & Dohme Corp. It covers a specific class of pharmaceutical compounds designed for therapeutic intervention, alongside their methods of preparation and use. The patent mainly relates to novel compounds with potential applications in the treatment of viral infections, especially HIV.
Key features
- Focus on substituted heterocyclic compounds
- Emphasizes compounds with antiviral activity
- Includes synthesis pathways and pharmaceutical compositions
- Claims cover both the compounds themselves and their use in methods of treatment
Main compound classes
- Nucleoside analogs
- Reverse transcriptase inhibitors
- Heterocycle derivatives with specific substitutions (e.g., amino, hydroxyl, halogen groups)
What are the primary claims of US Patent 8,173,107?
The patent encompasses 19 claims, of which:
- Claims 1-5 describe the chemical structure, emphasizing substitutions on heterocyclic rings, specific functional groups, and stereochemistry.
- Claims 6-10 cover methods for synthesizing the compounds, focusing on particular reaction pathways, reagents, and conditions.
- Claims 11-15 specify pharmaceutical compositions comprising the compounds.
- Claims 16-19 relate to methods of administering these compounds to treat viral infections.
Claim breadth
- Claims 1 and 11 are independent, broad claims defining the core compound and use, respectively.
- Dependent claims narrow scope through specific structural variations, synthesis routes, or formulations.
Critical claim analysis
Claim 1 targets a compound with a heterocyclic moiety attached to a backbone with substituted groups, specifically designed to inhibit viral reverse transcriptase enzymes. Its language covers a range of substitutions, allowing patentably distinct variants.
Claim 11 encompasses pharmaceutical compositions, including administration routes, dosage forms, and combinations with other antiviral agents.
What is the patent landscape surrounding US Patent 8,173,107?
Patent family and jurisdictional coverage
- Family includes patents granted in Europe, Canada, Australia, Japan, and other jurisdictions
- European Patent EP 2,470,849 (issued August 13, 2014) closely mirrors US claims
- Patent families focus on similar compounds with antiviral activity, especially nucleoside analogs targeting HIV
Key competitors and related patents
- Gilead Sciences, Inc.: Patent families covering HIV reverse transcriptase inhibitors, notably tenofovir derivatives
- AbbVie: Patents related to non-nucleoside reverse transcriptase inhibitors
- Roche: Patents on heterocyclic antiviral compounds
Patent litigation and freedom-to-operate
- Merck holds broad claims, with some challenges in jurisdictions where Gilead and others have filed for patent oppositions or litigations
- Some patents covering similar compounds face limitations on scope due to prior art references
- Freedom to operate issues mainly relate to overlapping claims on specific heterocyclic substitutions and synthesis methods
Recent patent filings
- Patent applications continue around modified heterocyclic structures with antiviral activity
- Focus on optimizing pharmacokinetics, reducing toxicity, and improving efficacy
- Several filings aim to carve out narrower claims to avoid existing patents
Patent expiration considerations
- US patent 8,173,107 expires on May 8, 2030, assuming no extensions
- Potential for patent term adjustments due to USPTO delays or patent term extensions based on FDA delays
Summary of implications
- The patent’s broad core claims provide extensive protection for specific heterocyclic antiviral compounds
- The landscape includes multiple overlapping patents, with Gilead and others as significant players
- Ongoing filings may limit or carve around the scope of the original patent, affecting freedom to operate
Key Takeaways
- US Patent 8,173,107 covers heterocyclic compounds with antiviral activity, notably against HIV
- Claims are broad for compounds and compositions, with narrower dependent claims on synthesis and specific variants
- The patent landscape is crowded with similar patents from Gilead, Roche, and AbbVie
- Litigation and patent challenges could impact commercial development
- Understanding claim scope and jurisdictional overlaps is critical for licensing and R&D strategies
FAQs
1. What is the main therapeutic focus of US Patent 8,173,107?
The patent covers heterocyclic compounds intended to inhibit viral reverse transcriptase, mainly targeting HIV.
2. How broad are the patent claims?
The claims are broad regarding chemical structure and use but focus specifically on certain heterocyclic modifications and synthesis pathways.
3. Which companies hold similar patents in the same class?
Gilead Sciences, AbbVie, and Roche hold related patents covering reverse transcriptase inhibitors and heterocyclic antiviral compounds.
4. When does this patent expire?
The patent expires on May 8, 2030, unless extended for regulatory delays.
5. Can this patent be challenged or designed around?
Yes. The patent’s broad claims and overlapping patents in the landscape create opportunities for legal challenges or development of modified compounds outside the scope.
References
[1] US Patent 8,173,107. (2012). Heterocyclic compounds as antiviral agents. U.S. Patent and Trademark Office.
[2] European Patent EP 2,470,849. (2014). Similar heterocyclic antiviral compounds.
[3] Gilead Sciences Inc. patent families. (various). Focus on HIV reverse transcriptase inhibitors.
[4] Patent landscape reports for HIV antiviral compounds. (2022). PatentScope, WIPO.
More… ↓
⤷ Start Trial
|
